Navigation Links
Pharmion Corporation Announces 2007 Operating Results
Date:2/19/2008

strative expenses totaled $143.2 million for the full year 2007 and $50.0 million for the fourth quarter of 2007. These amounts compare to selling, general and administrative expenses for the full year and fourth quarter of 2006 of $104.9 million and $32.0 million, respectively. As stated above, these full year and fourth quarter 2007 expenses include $8.6 million of expenses associated with the Company's pending acquisition by Celgene. Fourth quarter 2007 selling, general and administrative expenses increased significantly as compared to the first three quarters of 2007. This increase is due primarily to the expansion of the U.S. sales organization completed in the second half of 2007, launch preparation activities in Europe for thalidomide, and market research and medical education activities performed in connection with the release of overall survival data from the Vidaza Phase 3 study for the treatment of higher risk myelodysplastic syndromes patients.

As of December 31, 2007, Pharmion had $248.5 million in cash, cash equivalents and short-term investments, and no outstanding debt. This compares to the $136.2 million Pharmion had in cash, cash equivalents and short-term investments as of December 31, 2006, with the increase reflecting the receipt of $130 million in net proceeds from the Company's equity offering completed in June 2007.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Refo
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
2. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
4. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
5. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
6. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
7. VLST Corporation Announces Board and Executive Management Appointments
8. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
9. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
10. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Scientists, including University of Oregon chemist Geraldine ... scaffolds of self-assembling, synthetic proteins called peptoid nanosheets ... The accomplishment -- detailed this week in a ... Proceedings of the National Academy of Sciences ... design of the two-dimensional peptoid nanosheets that can ...
(Date:9/2/2014)... Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... approach for protecting personal data in Clinical Study ... and others. The document describes an approach to ... CSRs and other related clinical trial documents, and ... goal of the TransCelerate CSR Redaction approach is ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ... M.D., President and Chief Executive Officer, will present at the ... in New York on Tuesday, Sept. ... live and archived webcast of the presentation will be accessible ... "News & Events" section. About Oncothyreon ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... have created the first "active matrix" display using a ... toward realizing applications such as e-paper, flexible color monitors ... are made of "nanowires," tiny cylindrical structures that are ... The researchers used nanowires as small as 20 nanometers ...
... March 31 Chem Rx,Corporation (OTC Bulletin Board: ... services, announced today that it will hold a,conference ... 2008 outlook,on April 1, 2008 at 8:30 a.m. ... Steven C. Silva, President and Chief Operating,Officer, will ...
... ALTO, Calif., March 31 Varian, Inc.,(NasdaqGS: ... VF-5ht UltiMetal(TM),column for high temperature gas chromatography ... operating conditions. These highly durable columns,allow chemists ... temperatures, up,to 450 degrees Celsius. Based on ...
Cached Biology Technology:Engineers make first 'active matrix' display using nanowires 2Engineers make first 'active matrix' display using nanowires 3Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results 2New Capillary Column From Varian, Inc. Offers Durability and Performance for High Temperature GC and GC/MS 2
(Date:9/2/2014)... everyone has a tipping point. We all want to be ... is great enough. Now, scientists have confirmed the area of ... The result was published online this week in ... even if lying is beneficial," said Lusha Zhu, the study,s ... Tech Carilion Research Institute , where she works with Brooks ...
(Date:9/2/2014)... Sam Kean stops by Reactions this week to debunk ... that, despite what "Shark Week" may lead you to ... http://youtu.be/KhFygIoW_MA . , Kean,s book, "The Disappearing Spoon: ... History of the World from the Periodic Table of ... 10-episode video series produced for the newly launched American ...
(Date:9/2/2014)... for eating anything, including each other, camel crickets are ... Carolina State University finds that non-native camel cricket species ... , "The good news is that camel crickets don,t ... says Dr. Mary Jane Epps, a postdoctoral researcher at ... the research. , The research stems from a chance ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Researchers find Asian camel crickets now common in US homes 2
... State University and the University of Oxford are the ... how migrating birds use light and Earth,s weak magnetic ... 30, 2008, online issue of Nature that the photochemical ... weak magnetic fields similar to Earth,s when exposed to ...
... researchers have succeeded in wiping out established biofilms ... the bacteria,s own regulatory systems. Although the discovery ... offer insight into a dispersal mechanism for staph ... Biofilms are communities of bacteria that grow on ...
... the UN Conference on Climate Change (COP15) to be held ... to organise this conference as part of the run-up to ... try and capture some of the enormous research energy currently ... change. Thus, the focus of the conference is on providing ...
Cached Biology News:A model photochemical compass for bird navigation 2A model photochemical compass for bird navigation 3Turning on cell-cell communication wipes out staph biofilms 2Turning on cell-cell communication wipes out staph biofilms 3
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: